Huang et al. performed a study of 57 IPF patients on nintedanib and reported that higher baseline KL-6 (HR 4.52, 95% CI: 1.63–12.55, p = 0.004) was a significant risk factor for AE [33]. Here, MUC1 is linked to idiopathic pulmonary fibrosis.